<DOC>
	<DOCNO>NCT01073228</DOCNO>
	<brief_summary>This study conduct determine safety effect cognitive function investigational medication , EVP-6124 , individual mild moderate probable Alzheimer 's disease .</brief_summary>
	<brief_title>Safety Cognitive Function Study EVP-6124 Patients With Mild Moderate Alzheimer 's Disease</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , parallel , 24-week , Phase 2 safety/efficacy study three dose level EVP-6124 placebo evaluate . Eligible enrollment patient meet clinical criterion mild moderate probable Alzheimer 's disease either receive treatment AChEI medication stable dose presently take AChEI memantine co-medication . Patients randomize one follow group : 0.3 mg , 1 mg 2 mg Placebo . Approximately 400 subject randomize 4 treatment group . Study drug supply capsule orally administer daily total 24 week .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Central Nervous System Diseases</mesh_term>
	<mesh_term>Nicotinic Agonists</mesh_term>
	<criteria>Subjects Probable Alzheimer 's disease MiniMental State Examination ( MMSE ) score 14 24 inclusive screen CDRSB score ≥2 screen assessment Modified Hachinski Ischemic Score ( mHIS ) ≤4 screen Female subject ≥1 year postmenopausal surgically sterile Caregiver available ; live household , caregiver see subject least four time week Subject living home , senior residential setting , institutional set without need continuous nursing care General health status acceptable participation 24 week clinical trial administer General Participation another therapeutic clinical trial within 30 day Baseline Prior participation amyloid vaccination clinical study Inability swallow capsule Likely inability complete 24 week study Inability ≥75 % compliant singleblind placebo runin medication Inability adequately perform cognitive test History significant cardiovascular disease Major depression Psychosis History stroke within 18 month screen Head trauma Inability perform screen baseline evaluation</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>Central Nervous System disease</keyword>
	<keyword>Cognition</keyword>
</DOC>